NCT05264727Active, not recruitingPhase 4
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
This study is being done to better understand how amino acids alter the release of glucagon and insulin compared to glucose alone in health and disease.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 22 Feb 2022
- Start date
- 30 May 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Mayo Clinic
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT05264727
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 30
- From 30 May 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Contraindications to MRI (e.g., metal implants, claustrophobia).
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Contraindications to MRI (e.g., metal implants, claustrophobia).
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Contraindications to MRI (e.g., metal implants, claustrophobia).
Other illness
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
Lab values
- HbA1c ³ 8.5%
- HbA1c ≥ 6.5%
- Use of any glucose-lowering agents including metformin or sulfonylureas.
- HbA1c ≥ 6.5%.
- Use of any glucose-lowering agents including metformin or sulfonylureas.
Other
- BMI ≤ 28 Kg/M2
- Use of insulin or agents other than sulfonylureas or metformin.
- For female subjects: positive pregnancy test at the time of enrollment or study
- Hematocrit \< 35%
- TSH \< 0.4 or \> 5.5.
- Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.
- BMI ≤ 28 Kg/M2
- For female subjects: positive pregnancy test at the time of enrollment or study
- Hematocrit \< 35%
- TSH \< 0.4 or \> 5.5.
- Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.
- BMI ≥ 25 Kg/M\^2.
- For female subjects: positive pregnancy test at the time of enrollment or study.
- Hematocrit \< 35%.
- TSH \< 0.4 or \> 5.5.
- Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.
- Liver fat content ≥ 5% as determined by MRI using the proton density fat fraction (PDFF) technique.
Who the study is looking for
- HbA1c ≤ 8.5% (type 2 diabetic subjects).
- HbA1c ≤ 6.5% (obese and lean subjects).
- BMI ≥ 28 Kg/M\^2 (Obese subjects with and without type 2 diabetes).
- BMI ≤ 25 Kg/M\^2 (Lean subjects without type 2 diabetes).
- Use of sulfonylureas or metformin only (type 2 diabetec subjects).
- For female subjects: negative pregnancy test at the time of enrollment or study.
- No history of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- No active systemic illness or malignancy.
- No symptomatic macrovascular or microvascular disease.
- No contraindications to MRI (e.g., metal implants, claustrophobia).
- Hematocrit \> 35%.
- TSH \> 0.4 or \< 5.5.
- Consumption of \< 2 alcohol drinks per day or \< 14 per week or a negative AUDIT questionnaire.
- BMI ≥ 28 Kg/M2.
- \> 5% liver fat content, as determined by MRI using the proton density fat fraction (PDFF) technique.
- \- BMI ≤ 25 Kg/M\^2).
Age in the registry: 25 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic - Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.